To confirm these data in a larger dataset with clinical annotation, we evaluated the incidence of EGFR amplification (≥4.5 CN) in patients with breast cancer profiled by Caris Life Sciences (Caris), where the majority of patients profiled had metastatic breast cancer (Table 1). This evidence concerns the gene EGFR and breast carcinoma.